Injective and Microsoft are hosting an onchain agentic commerce event in Singapore on October 6, one day before the Token2049 conference. The session will demonstrate Injective’s infrastructure for autonomous AI agents that perform transactions without human intervention.
The partnership builds on the Nova Program, launched in May 2026 to support developers working at the intersection of AI and blockchain. Participants receive access to Microsoft Azure AI services, Injective’s development tools, and grants exceeding $10 000.
The Injective Foundation offers venture capital investments of up to $1 million for selected projects. The program, initially unveiled at the Hong Kong Web3 Festival, focuses on the Asian market and aims to foster innovation in agent-to-agent commerce.
Injective has integrated specific technical features for AI agents, including the ERC-8004 standard for verifiable identities, efficient fee routing for high-frequency trading, and x402 micropayments. The platform also supports a decentralized central limit order book.
As of mid-2026, Injective reported over $6,8 billion in volume related to real-world assets. Additionally, the company became an SEC-registered transfer agent in 2026, enabling it to manage official records of securities ownership and handle transfers.
